Experimental Therapeutic Strategies in Epilepsies Using Anti-Seizure Medications

Abstract

Epilepsies are among the most common neurological problems. The disease burden in patients with epilepsy is significantly high, and epilepsy has a huge negative impact on patients’ quality of life with epilepsy and their families. Anti-seizure medications are the mainstay treatment in patients with epilepsy, and around 70% of patients will ultimately control with a combination of at least two appropriately selected anti-seizure medications. However, in one-third of patients, seizures are resistant to drugs, and other measures will be needed. The primary goal in using experimental therapeutic medication strategies in patients with epilepsy is to prevent recurrent seizures and reduce the rate of traumatic events that may occur during seizures. So far, various treatments using medications have been offered for patients with epilepsies, which have been classified according to the type of epilepsy, the effectiveness of the medications, and the adverse effects. Medications such as Levetiracetam, valproic acid, and lamotrigine are at the forefront of these patients’ treatment. Epilepsy surgery, neuro-stimulation, and the ketogenic diet are the main measures in patients with medication-resistant epilepsies. In this paper, we will review the therapeutic approach using anti-seizure medications in patients with epilepsy. However, it should be noted that some of these patients still do not respond to existing treatments; therefore, the limited ability of current therapies has fueled research efforts for the development of novel treatment strategies. Thus, it seems that in addition to surgical measures, we should look for more specific agents that have less adverse events and have a greater effect in stopping seizures.

Flupirtine’s anticonvulsant role +/- celecoxib versus diazepam on induced generalized seizures and status epilepticus in mice

“…Epilepsy is a neurological disorder characterized by abnormal CNSelectrical activity and recurrent seizures. Epilepsy affects 65 million people worldwide, mainly neonates and geriatrics , thus, representing a personal and community major burden [1][2][3]. About one-third of patients remain resistant to treatment despite substantial increase in the available antiepileptic drugs [4].…”

An involvement of COX and 5‐LOX pathways in the penicillin‐ and pentylenetetrazole (PTZ)‐induced epilepsy models

“…In many cases, antiepileptic drugs (AEDs) can partially control seizures and help patients to maintain their everyday lives. Although advanced in antiepileptic drugs and research, seizures occur in approximately 30% of patients with epilepsy (Rahim et al, 2021). In this manner, many factors have essential roles in the pathophysiology of epilepsy, and we must consider these, including in ammation, in the treatment of epilepsy.…”

Using Dictyostelium to Advance Our Understanding of the Role of Medium Chain Fatty Acids in Health and Disease

“…Dictyostelium Research to Improve Our Understanding of the Cell and Developmental Mechanisms of MCFAs in Health and Disease Treatment D. discoideum has played a key role in research focused on identifying and characterizing the pleiotropic effects of MCFAs. This area of research was first initiated through studies on the short, branched chain fatty acid valproic acid (VPA; 2propylpentanoic acid), commonly used as a medicinal treatment for epilepsy and bipolar disorder (Fontana et al, 2020;Rahim et al, 2021). Surprisingly, the molecular mechanism of this drug has remained largely unclear (Terbach and Williams, 2009).…”